NCT00379951View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Urinary Tract Infection
Interventions
DRUG

ertapenem sodium

ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00379951 - A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) | Biotech Hunter | Biotech Hunter